Ninety Seconds
This week, we’re kicking off our “Ninety Seconds of What’s Next” video series, with a quick look at the two items I’ll be obsessed with this week: the pricing of COVID-19 therapeutics and presidential polling. — Brian
Recommended Value
Welcome to Recommended Value, the W2O hub for value, access, pricing and reimbursement intelligence.
It’s never been more critical to understand the value environment, and there is no better way to stay connected with what matters than our newsletters. Our weekly Value Report (subscribe here) offers a comprehensive review, each Friday, of the week that was.
Our Recommended Daily Value newsletter — available with a paid subscriptions (get your free trial here) — brings readers the day’s news, along with original analyses and commentary, providing the information needed to make decisions in real time.
The Latest
Today, W2O is launching Recommended Value, a hub for news and commentary about the way health care value, price, access and reimbursement. It extends the work we’ve been doing with our industry-leading newsletters for more than five years, allowing W2O to expand our analysis and curation and bring more visibility to these critical issues.
NEW: Biden and Trump representatives went deep on drug pricing in a Patients for Affordable Drugs NOW Town Hall. Here were our takeaways from the event.
Our 2020 Election Scorecard is updated with snapshots of how the health conversation is shaping the Senate race in four battleground states.
Peter Kolchinsky, RA Capital’s founder and managing partner, joins to talk about why so many of the policy ideas floated around drug-pricing are wrongheaded. Industry is going to have to give “a pound of flesh,” Kolchinsky argued, and he’s explicit on the business practices biopharma must abandon to get a fair system that still rewards innovation.
We made some bold predictions about drug-pricing in 2020 back in January. The crystal ball might have been too cloudy: we didn’t see the pandemic coming.
The Weekly Value Report
The Impact of COVID-19 on Minority Communities in America is a Functioning Tragedy
Our Lauren Oubre spoke with Dr. Robert Fullilove, Associate Dean for Community and Minority Affairs, Professor of Clinical Sociomedical Sciences at Columbia University about racial disparities in the United States and abroad, comparing COVID-19 with HIV and explaining how pharmaceutical companies have a role in bridging gaps in care.
Our Five Drug-Pricing Predictions for 2020
As the old Danish proverb goes, it’s hard to make predictions, especially about the future. That doesn’t stop us from — once a year — taking a stab at it. The value and pricing conversation is moving fast, making it critically important to try to think about what’s coming next.
Highlights from Our Redeeming Value Podcast
Oct. 20, 2020: Peter Kolchinsky on Where Drug-Pricing Policy Solutions Go Wrong
Listen Here
Sept. 29, 2020: Jason Shafrin on Where — and Why — ICER Really Matters
Listen Here
Sept. 16, 2020: Jason Buxbaum, Medicines and Life Expectancy
Listen here
RDV Image of the Week
Last week, we shared a new Health Affairs study that highlighted the rise in spending on orphan drugs for privately insured children. Ten orphan drugs accounted for 52.9% of total pediatric orphan drug spending in 2018, according to the study.
Here’s a closer look at these drugs and their share of total pediatric orphan drug spending:
Say “hi.”
Contact Us
